Thu. Jul 7th, 2022
Gland Pharma gets Sebi approval for Rs 6,000 crore IPO, set for first listing of an Indian firm with a Chinese parent The IPO is a mixture of primary and secondary issue of shares with both China’s Fosun group and the founders of Gland Pharma due to dilute shares. Gland Pharma may look to launch the IPO in November 2020 in first listing by an Indian drug maker in three years